The Effect of Imatinib on the Fetus Growth and Development of a Pregnant Woman Involved with CML, a Case Report and a Literature Review

Authors: Tootoonchi P*

DOI: 10.23880/jcstm-16000124

Volume 6, Issue 1

Abstract

Chronic Myeloid leukemia (CML) is a chronic myeloproliferative leukemia which may involve the women during their fertile period of life. Despite the standard therapy for CML is targeted therapy with tyrosine kinase inhibitor, most authorities recommend to withdraw the treatment with the maternal pregnancy. In this case report, we present a known case of CML who was under standard treatment with Imatinib and Hydroxyurea for 5 years and continued her therapy despite her unplanned pregnancy till 2 weeks before her baby’s delivery. She delivered a full term low birth weight male after 40 weeks and 3.5 days of her last menstrual period. His physical examination has shown that he was a healthy male without any congenital anomaly.

Keywords: Pregnancy; Imatinib; Chronic Myeloid Leukemia; Thyrosine kinase Inhibitor

View PDF